MedTrace Logo

Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense

NCT01425788 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2015-06-26

No results posted yet for this study

Summary

The purpose of this trial is to investigate the tolerability of Osiris Phleum pratense used with 2 simplified up-dosing schedules compared to the up-dosing schedule used in current practice.

Conditions

  • Rhino-conjunctivitis

Interventions

BIOLOGICAL

Osiris Phleum pratense

BIOLOGICAL

Osiris Phleum pratense

BIOLOGICAL

Osiris Phleum pratense

Sponsors & Collaborators

  • Ergomed

    collaborator INDUSTRY

  • ACM Pivotal Global Central Laboratory

    collaborator INDUSTRY

  • Brecon Pharmaceuticals Ltd

    collaborator UNKNOWN

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Piotr Kuna, Prof.med · Uniwersytecki Szpital Kliniczny Nr1, Lodz, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-11-30
Completion
2012-02-29

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01425788 on ClinicalTrials.gov